News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CHEMICON International And Thromb-X, NV Enter Into Agreement For Exclusive Sale And Marketing Of New Embryonic Stem Cell Tissue Culture Media



10/19/2005 5:11:57 PM

Thromb-X N.V., the R&D division of ThromboGenics Ltd., and Chemicon International, a division of Serologicals Corporation (NASDAQ/NM: SERO), today announced the signing of an exclusive global agreement to market embryonic stem (ES) cell reagents developed by Thromb-X. The centerpiece of this agreement is the commercialization of the TX-WES culture medium that was specifically developed to enable the derivation of new "non-permissive" strains and to rescue existing ES cell lines.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES